Rayner launches new ‘Dropless’ campaign
Posted on 20/11/2024
Rayner, a global manufacturer of products for cataract surgery based in the United Kingdom, has launched a campaign to promote a dropless regimen with OMIDRIA® for postoperative cataract care.
According to studies, up to 92% of patients struggle with self-administering postoperative eye drops. Inaccuracy with eye drops poses the risk of inconsistent or missed doses and incorrect application. This can place the success of cataract surgery in the hands of the patient, placing an additional burden on patients, surgeons, and clinic staff. This latest campaign promotes OMIDRIA® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) as a central part of a dropless regimen, removing the need for up to 250 patient-administered eye drop doses. The move to dropless cataract surgery has the potential for significant environmental impact, reducing up to 12 million individual plastic eye drop bottles every year in the US alone.
The launch kicked off in October at the American Academy of Ophthalmology meeting in Chicago, where Drs. Cathleen McCabe, Paul Singh, and Brian Shafer presented preliminary data from a US multicenter, randomized, prospective study comparing standard of care topical eye drops vs intracameral OMIDRIA, subconjunctival triamcinolone, and intracameral moxifloxacin in patients undergoing bilateral cataract surgery. These interim results showed no statistically significant difference between the OMIDRIA dropless regimen and a standard topical regimen in inflammation and mean retinal thickness on days 1, 8, and 30; neither arm demonstrated any inflammation by day 30. Patients highly preferred the OMIDRIA dropless regimen over standard of care (90% vs 42%).
OMIDRIA is the only FDA-approved NSAID for use during cataract surgery, indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative pain. Studies have also shown OMIDRIA to reduce complications such as intraoperative floppy iris syndrome (IFIS) and cystoid macular edema (CME), as well as enhance patients’ cataract surgery experience. OMIDRIA achieves a 548x higher concentration of ketorolac in the vitreous than topical drops, which may help reduce CME risk without the need for a topical corticosteroid.
To learn more about how OMIDRIA streamlines cataract surgery and places control of surgical outcomes in the hands of surgeons, visit www.omidria.com
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
Portions of the information included in this press release is based on preliminary data and is provided for informational purposes only. The results and conclusions presented herein are subject to change as further analysis and validation are conducted. These findings have not yet been peer-
reviewed or confirmed through additional studies, and therefore, should not be interpreted as definitive or conclusive.
Readers are cautioned not to place undue reliance on the preliminary data, which may differ from final results or outcomes.
A dropless approach with OMIDRIA may not be for everyone. Rayner does not recommend any specific combination use of products.
©2024 Rayner Group, all rights reserved. ‘Rayner’ and ‘OMIDRIA’ are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners. US-OM-2400080 11/24